These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Recurrence rate after a first venous thrombosis in patients with familial thrombophilia. Vossen CY; Walker ID; Svensson P; Souto JC; Scharrer I; Preston FE; Palareti G; Pabinger I; van der Meer FJ; Makris M; Fontcuberta J; Conard J; Rosendaal FR Arterioscler Thromb Vasc Biol; 2005 Sep; 25(9):1992-7. PubMed ID: 15976329 [TBL] [Abstract][Full Text] [Related]
6. Venous thromboembolism in the ICU and reversal of bleeding on anticoagulants. DeLoughery TG Crit Care Clin; 2005 Jul; 21(3):497-512. PubMed ID: 15992670 [TBL] [Abstract][Full Text] [Related]
13. [Initial results of the PROTECT Study publicized. Stroke patients need effective thrombosis prevention]. Diener HC MMW Fortschr Med; 2005 Jun; 147(22):50. PubMed ID: 15977636 [No Abstract] [Full Text] [Related]
14. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Leizorovicz A; Cohen AT; Turpie AG; Olsson CG; Vaitkus PT; Goldhaber SZ; Circulation; 2004 Aug; 110(7):874-9. PubMed ID: 15289368 [TBL] [Abstract][Full Text] [Related]
15. Venous thromboembolism: "... an ounce of prevention is worth a pound of cure". Goldhaber SZ; Ageno W Thromb Haemost; 2015 Jun; 113(6):1174-5. PubMed ID: 25947622 [No Abstract] [Full Text] [Related]
16. [Therapy of pulmonary embolism. Rivaroxaban is superior to standard therapy]. Einecke D MMW Fortschr Med; 2012 Apr; 154(7):24. PubMed ID: 22558862 [No Abstract] [Full Text] [Related]
17. Thrombophilic abnormalities and recurrence of venous thromboembolism in patients treated with standardized anticoagulant treatment. Santamaria MG; Agnelli G; Taliani MR; Prandoni P; Moia M; Bazzan M; Guazzaloca G; Ageno W; Bertoldi A; Silingardi M; Tomasi C; Ambrosio GB; Thromb Res; 2005; 116(4):301-6. PubMed ID: 16038714 [TBL] [Abstract][Full Text] [Related]
18. Prognostic factors for recurrence of venous thromboembolism (VTE) or bleeding during long-term secondary prevention of VTE with ximelagatran. Eriksson H; Lundström T; Wåhlander K; Clason SB; Schulman S; Thromb Haemost; 2005 Sep; 94(3):522-7. PubMed ID: 16268466 [TBL] [Abstract][Full Text] [Related]
19. What is the optimal pharmacological prophylaxis for the prevention of deep-vein thrombosis and pulmonary embolism in patients with acute ischemic stroke? Kamphuisen PW; Agnelli G Thromb Res; 2007; 119(3):265-74. PubMed ID: 16674999 [TBL] [Abstract][Full Text] [Related]
20. Risk assessment and novel therapeutic approaches: reducing the incidence and recurrence of deep vein thrombosis in the surgical patient. Conclusion. Laird L; Wille-Jørgensen P Orthopedics; 2000 Jun; 23(6 Suppl):s655-6. PubMed ID: 10875432 [No Abstract] [Full Text] [Related] [Next] [New Search]